HC Wainwright Has Positive Forecast for Septerna Q3 Earnings

Septerna, Inc. (NASDAQ:SEPN) – Analysts at HC Wainwright boosted their Q3 2026 earnings estimates for shares of Septerna in a research report issued on Wednesday, August 12th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.31) for the quarter, up from their prior estimate of ($0.66). HC Wainwright has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for Septerna’s current full-year earnings is ($1.54) per share. HC Wainwright also issued estimates for Septerna’s Q4 2026 earnings at ($0.35) EPS, FY2026 earnings at ($1.15) EPS, Q1 2027 earnings at ($0.33) EPS, Q2 2027 earnings at ($0.27) EPS, Q3 2027 earnings at ($0.37) EPS, Q4 2027 earnings at ($0.44) EPS and FY2027 earnings at ($1.41) EPS.

Septerna (NASDAQ:SEPN) last released its earnings results on Monday, August 10th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.14. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.59%. The business had revenue of $26.75 million for the quarter, compared to analyst estimates of $19.22 million.

Several other equities research analysts also recently weighed in on the stock. Wells Fargo & Company upped their target price on shares of Septerna from $48.00 to $50.00 and gave the stock an “overweight” rating in a research note on Wednesday. Guggenheim raised their price objective on shares of Septerna from $45.00 to $51.00 and gave the stock a “buy” rating in a research report on Tuesday. JonesTrading increased their price target on Septerna from $43.00 to $62.00 and gave the stock a “buy” rating in a report on Thursday. Truist Financial increased their target price on Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. Finally, Stifel Nicolaus set a $49.00 price target on Septerna in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Septerna has a consensus rating of “Moderate Buy” and an average price target of $51.33.

Septerna Price Performance

Shares of SEPN opened at $45.14 on Friday. Septerna has a 1-year low of $10.74 and a 1-year high of $51.10. The firm has a 50-day simple moving average of $35.57 and a two-hundred day simple moving average of $29.54. The stock has a market cap of $2.11 billion, a PE ratio of -83.59 and a beta of 2.29.

Institutional Investors Weigh In On Septerna

Hedge funds have recently modified their holdings of the business. Deutsche Bank AG lifted its holdings in shares of Septerna by 5.3% during the 4th quarter. Deutsche Bank AG now owns 14,879 shares of the company’s stock worth $415,000 after acquiring an additional 744 shares during the period. Global Retirement Partners LLC bought a new position in Septerna in the 4th quarter valued at $35,000. JPMorgan Chase & Co. raised its stake in shares of Septerna by 15.0% during the second quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock worth $107,000 after buying an additional 1,315 shares during the last quarter. PharVision Advisers LLC increased its holdings in Septerna by 17.5% in the third quarter. PharVision Advisers LLC now owns 11,932 shares of the company’s stock valued at $224,000 after purchasing an additional 1,780 shares during the last quarter. Finally, Nuveen LLC boosted its position in shares of Septerna by 7.7% during the fourth quarter. Nuveen LLC now owns 25,798 shares of the company’s stock worth $719,000 after purchasing an additional 1,837 shares in the last quarter.

Insiders Place Their Bets

In related news, insider Samira Shaikhly sold 2,178 shares of the company’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $35.18, for a total transaction of $76,622.04. Following the transaction, the insider directly owned 793 shares of the company’s stock, valued at approximately $27,897.74. The trade was a 73.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Elizabeth Bhatt sold 25,000 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $44.00, for a total value of $1,100,000.00. Following the completion of the transaction, the chief operating officer directly owned 174,209 shares in the company, valued at approximately $7,665,196. The trade was a 12.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 72,828 shares of company stock worth $2,684,314. 5.80% of the stock is owned by corporate insiders.

Key Septerna News

Here are the key news stories impacting Septerna this week:

• Positive Sentiment: Analyst sentiment strengthened: JonesTrading raised its price target from $43 to $62 and assigned a “buy” rating, while HC Wainwright lifted its target from $40 to $60 and maintained a “buy” rating. JonesTrading Septerna price target HC Wainwright Septerna price target
• Positive Sentiment: Wells Fargo raised its price target from $48 to $50 and reiterated an “overweight” rating. The consensus view remains “Moderate Buy,” with an average target of approximately $51.33. Wells Fargo Septerna price target
• Positive Sentiment: Septerna’s latest quarterly results exceeded expectations. The company reported a loss of $0.29 per share versus the expected $0.43 loss, while revenue of $26.75 million surpassed the $19.22 million consensus estimate. Septerna earnings report
• Neutral Sentiment: The stock has rallied sharply, trading near its 12-month high. With a market capitalization of about $2.1 billion and continuing expected losses, investors may be reassessing valuation following the earnings-driven advance.
• Negative Sentiment: COO Elizabeth Bhatt sold 25,000 shares at an average price of $44 for approximately $1.1 million, reducing her ownership by 12.55%. She still holds 174,209 shares, but the insider sale may be weighing on sentiment and prompting profit-taking after the recent rise. Septerna insider sale filing

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.